ORCHESTRA BIOMED HOLDINGS IN (OBIO)
US68572M1062 - Common Stock
ORCHESTRA BIOMED HOLDINGS IN
NASDAQ:OBIO (9/27/2023, 7:00:02 PM)
After market: 7.93 0 (0%)7.93
+0.04 (+0.51%)
Company Profile
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania. The company went IPO on 2020-08-04. The Company’s flagship product candidates are Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of artery disease, the leading cause of mortality worldwide, and BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension, a significant risk factor for death worldwide. Virtue SAB is a drug/device combination product candidate for the treatment of artery disease designed to deliver an extended-release formulation of sirolimus, SirolimusEFR, during balloon angioplasty without the need for balloon coating or a permanent implant. BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate, substantial and persistent reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction.
Company Info
ORCHESTRA BIOMED HOLDINGS IN
150 Union Square Drive
New Hope PENNSYLVANIA
P: 16463439298.0
Employees: 0
OBIO News
8 days ago - ChartmillIn today's session, these stocks are experiencing unusual volume.Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
8 days ago - The Motley FoolWhy Shares of Orchestra BioMed Jumped TuesdayThe company got approval from the FDA to go ahead with a pivotal study for a hypertension therapy.
9 days ago - Orchestra BioMed Holdings, Inc.Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker PatientsHypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually...
2 months ago - Orchestra BioMed Holdings, Inc.Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business UpdateU.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent...
OBIO Twits
Here you can normally see the latest stock twits on OBIO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
